·7·中国现代药物应用2024年4月第18卷第7期ChinJModDrugAppl,Apr2024,Vol.18,No.7沙库巴曲缬沙坦联合阿托伐他汀对冠心病合并心力衰竭患者的临床效果与安全性评价张勇【摘要】目的探讨沙库巴曲缬沙坦联合阿托伐他汀对冠心病合并心力衰竭患者的临床效果与安全性。方法120例冠心病合并心力衰竭患者,随机分为观察组和对照组,每组60例。观察组接受沙库巴曲缬沙坦和阿托伐他汀联合治疗,对照组接受马来酸依那普利和阿托伐他汀联合治疗。比较两组治疗后心功能分级,治疗效果,治疗前后收缩压(SBP)、舒张压(DBP),不良反应发生情况。结果观察组治疗后心功能分级优于对照组,但差异无统计学意义(P>0.05)。观察组总有效率76.67%明显高于对照组56.67%,差异有统计学意义(P<0.05)。治疗后,观察组SBP和DBP分别为(116.25±16.35)、(79.58±8.36)mmHg(1mmHg=0.133kPa),明显低于对照组的(125.36±15.36)、(86.63±8.25)mmHg,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论沙库巴曲缬沙坦与他汀类药物联合治疗冠心病合并心力衰竭患者的临床效果良好,安全性较高,可以为医生提供更准确的指导,助其做出适当的治疗选择。【关键词】心力衰竭；冠心病；沙库巴曲缬沙坦；阿托伐他汀；临床效果；安全性DOI：10.14164/j.cnki.cn11-5581/r.2024.07.002Clinicalefficacyandsafetyevaluationofcombinationtherapywithsacubitril-valsartanandatorvastatininpatientswithcoronaryheartdiseaseandheartfailureZHANGYong.CardiovascularDepartment,ZouchengPeople'sHospital,Zoucheng273500,China【Abstract】ObjectiveToexploretheclinicalefficacyandsafetyofcombinationtherapywithsacubitril-valsartanandatorvastatininpatientswithcoronaryheartdiseaseandheartfailure.MethodsAtotalof120patientswithcoronaryheartdiseaseandheartfailurewererandomlydividedintoanobservationgroupandacontrolgroup,with60casesineachgroup.Theobservationgroupreceivedthecombinedtreatmentofsacubitril-valsartanandatorvastatin,andthecontrolgroupreceivedthecombinedtreatmentofenalaprilmaleateandatorvastatin.Theheartfunctiongradingaftertreatment,treatmenteffect,andsystolicbloodpressure(SBP)anddiastolicbloodpressure(DBP)beforeandaftertreatment,andoccurrenceofadversereactionswerecomparedbetweenthetwogroups.ResultsTheheartfunctiong...
